TG Therapeutics, Inc. $TGTX Shares Acquired by Commonwealth of Pennsylvania Public School Empls Retrmt SYS

Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its position in TG Therapeutics, Inc. (NASDAQ:TGTX) by 1,221.4% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 422,078 shares of the biopharmaceutical company’s stock after acquiring an additional 390,137 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS owned about 0.27% of TG Therapeutics worth $15,191,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. Ameritas Advisory Services LLC acquired a new stake in shares of TG Therapeutics in the second quarter valued at about $25,000. SVB Wealth LLC acquired a new stake in shares of TG Therapeutics during the 1st quarter worth about $37,000. Private Wealth Asset Management LLC purchased a new stake in TG Therapeutics in the 2nd quarter worth approximately $37,000. Brooklyn Investment Group grew its holdings in TG Therapeutics by 2,159.2% in the first quarter. Brooklyn Investment Group now owns 1,604 shares of the biopharmaceutical company’s stock valued at $63,000 after purchasing an additional 1,533 shares during the period. Finally, CWM LLC grew its holdings in shares of TG Therapeutics by 16.2% during the 1st quarter. CWM LLC now owns 2,085 shares of the biopharmaceutical company’s stock worth $82,000 after purchasing an additional 290 shares during the period. Institutional investors and hedge funds own 58.58% of the company’s stock.

Insider Transactions at TG Therapeutics

In other news, Director Sagar Lonial sold 20,852 shares of the stock in a transaction on Thursday, September 11th. The stock was sold at an average price of $32.24, for a total transaction of $672,268.48. Following the transaction, the director directly owned 94,061 shares of the company’s stock, valued at $3,032,526.64. This represents a 18.15% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 10.64% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently issued reports on TGTX. HC Wainwright initiated coverage on TG Therapeutics in a report on Monday, October 6th. They issued a “buy” rating and a $60.00 price target for the company. Weiss Ratings restated a “hold (c+)” rating on shares of TG Therapeutics in a research report on Thursday. B. Riley raised shares of TG Therapeutics to a “strong-buy” rating in a research note on Tuesday, November 4th. JPMorgan Chase & Co. upped their target price on TG Therapeutics from $46.00 to $49.00 and gave the company an “overweight” rating in a research note on Monday, November 3rd. Finally, Wall Street Zen upgraded shares of TG Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $50.25.

TG Therapeutics Price Performance

Shares of NASDAQ:TGTX opened at $31.00 on Monday. The company has a quick ratio of 2.96, a current ratio of 3.86 and a debt-to-equity ratio of 0.89. The company’s fifty day moving average is $33.90 and its 200 day moving average is $34.23. The stock has a market cap of $4.92 billion, a PE ratio of 83.78 and a beta of 1.95. TG Therapeutics, Inc. has a 52 week low of $25.28 and a 52 week high of $46.48.

TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings data on Monday, November 3rd. The biopharmaceutical company reported $2.43 EPS for the quarter, topping the consensus estimate of $0.24 by $2.19. The business had revenue of $161.71 million during the quarter, compared to analyst estimates of $152.12 million. TG Therapeutics had a net margin of 13.31% and a return on equity of 26.05%. TG Therapeutics’s quarterly revenue was up 92.7% compared to the same quarter last year. During the same period last year, the business posted $0.02 earnings per share. TG Therapeutics has set its FY 2025 guidance at EPS. Research analysts anticipate that TG Therapeutics, Inc. will post 0.08 earnings per share for the current year.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.